We regret to report that long term Biogen Inc. (NASDAQ:BIIB) shareholders have had that experience, with the share price dropping 20% in three years, versus a market return of about 89%.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is willing to ...

At $310.58, the average BIIB stock price target of $310.58 suggests a modest upside potential of 1.8% from current levels. Biogen stock has rallied over 27% so far this year. IQVIA Holdings (IQV ...

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 30% over the last three months. Given the company's impressive performance, we decided to study its ...

Another notable valuation metric for BIIB is its P/B ratio of 3.26. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities.

Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session. This move lagged the S&P 500's daily loss of 0.74%. Elsewhere, the Dow lost 0.9% ...

In the latest market close, Biogen Inc. (BIIB) reached $247.52, with a +1.1% movement compared to the previous day. This change outpaced the S&P 500's 0.76% gain on the day. Elsewhere, the Dow ...

The average BioNTech stock price prediction of $211 implies 42.7% upside potential. Illumina (ILMN) Stock Illumina offers DNA sequencing and array-based solutions for genetic and genomic analysis.

VIDEO: Nasdaq 100 Movers: BIIB, GILD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.